The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback